Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
Qiuyan ChenLinquan TangNa LiuFeng HanLing GuoShanshan GuoJianwei WangHuai LiuYanfang YeLu ZhangLiting LiuPan WangYingqin LiQingmei HeXiaoqun YangQingnan TangYang LiYuJing LiangXueSong SunChuanmiao XieYunxian MoYing GuoRui SunHaoyuan MoKajia CaoXiang GuoMusheng ZengHaiqiang MaiJun MaPublished in: Cancer communications (London, England) (2018)
The recommended famitinib dose for phase II trial is 20 mg with CCRT for patients with local advanced NPC. D-CEUS is a reliable and early measure of efficacy for famitinib therapies. Further investigation is required to confirm the effects of famitinib plus chemoradiotherapy.